Shifting treatment paradigm in the management of Chronic Lymphocytic Leukemia - 13 Nov 2020

Part 1 - Welcome and Introduction - Dr. Shweta Surve, AstraZeneca
Part 2 - Importance of Prognostic Marker Testing in Treatment-Naive Patients with CLL - Dr. Renu
Part 3 - Current Role of chemo immunotherapy in management of CLL - Dr. Amit Upadhyay, Delhi
Part 4 - Clinical experience with 1st Generation BTKi & real-world challenges - Dr. Priyanka Samal
Part 5 - Treatment of Treatment naive Chronic Lymphocytic Leukemia - Dr. Versha Benerji, Canada
Part 6 - Panel Discussion - Dr M B Agarwal, Mumbai
Part 7 - Vote of Thanks - Dr. Shweta Surve, AstraZeneca